Kihyun Kım

Namseoul University — South Korea

Medicine · Health Sciences

56h-index15.2kcitations779works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(359), Protein Degradation and Inhibitors(142), Peptidase Inhibition and Analysis(98), Cancer Treatment and Pharmacology(78), Lymphoma Diagnosis and Treatment(74)

Publications776 total

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine·2025· 5 cited
Real-world outcomes of SLiM-only multiple myeloma: Korean Multicenter Retrospective analysis (KMM2401 study)
2025Open Access
Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
Blood·2025· 1 citedOpen Access
Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis
Blood·2025Open Access
Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial
Blood·2025Open Access
Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years
Blood·2025Open Access
Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Blood·2025Open Access
Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1
Blood·2025Open Access
Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: On the verge of its prime time
Seminars in Hematology·2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
The Lancet Haematology·2025· 1 cited
Clinical Relevance of Circulating Myeloma Cell Quantification and Multiple Myeloma Staging System
The Journal of Liquid Biopsy·2025Open Access
Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone
International Journal of Hematology·2025
Subject-Independent sEMG-Based Prosthetic Control Using MAMBA2 with Domain Adaptation
2025
Unique <i>TTR</i> Variants D38A and M13dup Among Korean Patients with Hereditary Transthyretin Amyloidosis: A Retrospective Single-Center Cohort Study
Annals of Laboratory Medicine·2025Open Access
Parallel Journeys, Similar Challenges, and Different Reasons: Navigating Life Challenges in Multiple Myeloma from the Perspectives of Patients and Caregivers
2025Open Access
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
Blood Cancer Journal·2025Open Access
Establishment of the Erosion Control Line from Long-Term Beach Survey Data on the Macro-Tidal Coast
Journal of Marine Science and Engineering·2025· 1 citedOpen Access
Measures of family process: Psychometric properties and invariance testing across South Koreans, Korean Chinese, and Korean Americans.
Developmental Psychology·2025Open Access
Response kinetics as a dynamic prognostic marker in patients with multiple myeloma
2025Open Access
Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 39Next →

Frequent Co-authors

Keunchil Park(13), Won Seog Kim(13), Won Ki Kang(12), Meletios Α. Dimopoulos(11), Young Hyeh Ko(11), Chul Won Jung(10), Philippe Moreau(8), Albert Oriol(8), Seok Jin Kim(8), Xavier Leleu(6), Kenshi Suzuki(6), Jeeyun Lee(6), Cheolwon Suh(6), Joon Oh Park(6), Young‐Hyuck Im(6), Mark H. Lee(6), Paul G. Richardson(5), Ivan Špıčka(5), Michèle Cavo(5), Roman Hájek(5)